A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany

[1]  D. El-Hammady,et al.  Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt , 2021, Rheumatology International.

[2]  B. Poyraz,et al.  Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey , 2021, Rheumatology International.

[3]  M. Dougados.  Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic , 2021, The Lancet Rheumatology.

[4]  P. Hoff,et al.  Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort , 2021, Annals of the Rheumatic Diseases.

[5]  Andrew T. Kroger,et al.  American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1 , 2021, Arthritis & Rheumatology.

[6]  P. Emery,et al.  COVID-19 vaccination and antirheumatic therapy , 2021, Rheumatology.

[7]  A. Skapenko,et al.  Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines , 2021, RMD Open.

[8]  H. Schulze-Koops,et al.  [Vaccination against SARS-CoV-2 in inflammatory rheumatic diseases : Recommendations of the German Society for Rheumatology for physicians and patients]. , 2021, Zeitschrift fur Rheumatologie.

[9]  K. Kadkhoda.  Herd Immunity to COVID-19. , 2021, American journal of clinical pathology.

[10]  T. Burki.  Herd immunity for COVID-19 , 2020, The Lancet Respiratory Medicine.

[11]  O. Zimba,et al.  Reporting Survey Based Studies – a Primer for Authors , 2020, Journal of Korean medical science.

[12]  A. Fazaa,et al.  Do immunosuppressive agents hamper the vaccination response in patients with rheumatic diseases? A review of the literature. , 2020, Therapie.

[13]  M. Dougados,et al.  Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD , 2019, RMD Open.

[14]  M. Dougados,et al.  2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2019, Annals of the rheumatic diseases.

[15]  E. Lee,et al.  Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial , 2019, Annals of the rheumatic diseases.

[16]  E. Lee,et al.  Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial , 2018, Annals of the rheumatic diseases.

[17]  M. Genovese,et al.  Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept , 2016, BMC Musculoskeletal Disorders.

[18]  E. Lee,et al.  The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[19]  C. Gabay,et al.  Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases – a longitudinal study , 2015, Arthritis Research & Therapy.

[20]  T. Barnetche,et al.  Effect of Methotrexate, Anti–Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis , 2014, Arthritis care & research.

[21]  N. Nishimoto,et al.  Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab , 2014, Modern rheumatology.

[22]  A. Fichtner,et al.  Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial , 2014, The Journal of Rheumatology.

[23]  E. Bonfá,et al.  Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis , 2013, Arthritis care & research.

[24]  E. Bonfá,et al.  TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients , 2012, Rheumatology.

[25]  A. Chioato,et al.  Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study , 2012, Clinical and Vaccine Immunology.

[26]  K. Oishi,et al.  Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[27]  F. Rozenberg,et al.  Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study. , 2012, Rheumatology.

[28]  R. Panush.  Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study , 2012 .

[29]  C. Combescure,et al.  Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. , 2011, Arthritis and rheumatism.

[30]  E. Mendelson,et al.  The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. , 2011, Vaccine.

[31]  E. Mendelson,et al.  The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. , 2010, Seminars in arthritis and rheumatism.

[32]  C. Kallenberg,et al.  Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. , 2010, Arthritis and rheumatism.

[33]  H. Argani,et al.  Antibody Response to Influenza Immunization in Kidney Transplant Recipients Receiving either Azathioprine or Mycophenolate: A Controlled Trial , 2008, American Journal of Nephrology.

[34]  J. Ablin,et al.  Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response , 2007, Annals of the rheumatic diseases.

[35]  E. Mendelson,et al.  Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers , 2005, Annals of the rheumatic diseases.

[36]  G. Jönsson,et al.  Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. , 2006, Rheumatology.